Edition:
United Kingdom

Moleculin Biotech Inc (MBRX.OQ)

MBRX.OQ on NASDAQ Stock Exchange Capital Market

1.83USD
20 Apr 2018
Change (% chg)

$-0.04 (-2.14%)
Prev Close
$1.87
Open
$1.85
Day's High
$1.85
Day's Low
$1.83
Volume
3,305
Avg. Vol
136,930
52-wk High
$3.74
52-wk Low
$0.71

Select another date:

Wed, Feb 7 2018

BRIEF-Moleculin Biotech Inc - Has Been Able To Show Promising Tumor Suppression Activity With Its Inhibitor Of Glycolysis, Wp1122

* MOLECULIN BIOTECH INC - HAS BEEN ABLE TO SHOW PROMISING TUMOR SUPPRESSION ACTIVITY WITH ITS INHIBITOR OF GLYCOLYSIS, WP1122 Source text for Eikon: Further company coverage:

BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor

* MOLECULIN EXPANDS LEUKEMIA DEVELOPMENT PORTFOLIO WITH IMMUNO-STIMULATING STAT3 INHIBITOR

BRIEF-Moleculin Announces Polish Approval For Leukemia Clinical Trial

* MOLECULIN ANNOUNCES POLISH APPROVAL FOR LEUKEMIA CLINICAL TRIAL

BRIEF-Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA

* MOLECULIN BIOTECH SAYS ON NOV 29, CO WAS INFORMED THAT INVESTIGATIONAL NDA FOR PHASE I TRIAL OF WP1066 HAS BEEN ALLOWED BY FDA - SEC FILING Source text: [http://bit.ly/2jcVpeo] Further company coverage:

BRIEF-Moleculin Biotech Q3 loss per share $0.14‍​

* Moleculin Biotech Inc reports financial results for the third quarter ended september 30, 2017

BRIEF-Moleculin appoints Sandra Silberman as chief medical officer

* Moleculin appoints Dr. Sandra Silberman as chief medical officer -- new products Source text for Eikon: Further company coverage:

BRIEF-Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors

* Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors

BRIEF-Moleculin requests for clinical trial authorization to study annamycin

* Moleculin Biotech - ‍submitted request for clinical trial authorization to study annamycin for treating relapsed/refractory acute myeloid leukemia in Poland Source text for Eikon: Further company coverage:

Select another date: